NCT04512833 CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis
| NCT ID | NCT04512833 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing 302 Hospital |
| Condition | Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2020-08-12 |
| Primary Completion | 2023-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2020-08-12 with a primary completion date of 2023-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.
Eligibility Criteria
Inclusion Criteria: * Primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology * Unfeasible or refusing to undergo other treatments; * Residual normal liver volume ≥700 cc; * With decompensated cirrhosis (Child-Pugh B or C classification); * Without portal vein tumor thrombus; * Eastern Cooperative Oncology Group (ECOG) score 0-1; * Distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm； * Rejecting other therapies such as resection, liver transplantation, etc. * Platelet count≥50 × 109/L, white blood count≥1.5 × 109/L; * Patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative. Exclusion Criteria: * With Tumor thrombus； * With extrahepatic metastasis; * With lymph node involvement.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04512833 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 80 Years, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04512833 currently recruiting?
Yes, NCT04512833 is actively recruiting participants. Contact the research team at 519299998@qq.com for enrollment information.
Where is the NCT04512833 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT04512833 clinical trial?
NCT04512833 is sponsored by Beijing 302 Hospital. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.